The Journal of Experimental Medicine
IN Cell Analyzer 2000
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20091240
The Journal of Experimental Medicine, Vol. 206, No. 11, 2543-2555
The Rockefeller University Press, 0022-1007 $30.00
© Paruchuri et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 4064K)
Right arrow PDF+supp data (4823K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Paruchuri, S.
Right arrow Articles by Boyce, J. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paruchuri, S.
Right arrow Articles by Boyce, J. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Article

Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12 receptor

Sailaja Paruchuri1,3, Hiroyuki Tashimo1,3, Chunli Feng3, Akiko Maekawa1,3, Wei Xing1,3, Yongfeng Jiang1,3, Yoshihide Kanaoka1,3, Pamela Conley4, and Joshua A. Boyce1,2,3

1 Department of Medicine and 2 Department of Pediatrics, Harvard Medical School, Boston, MA 02115
3 Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA 02115
4 Portola Pharmaceuticals, San Franciso, CA 94127

CORRESPONDENCE Joshua A. Boyce: jboyce{at}rics.bwh.harvard.edu

Of the potent lipid inflammatory mediators comprising the cysteinyl leukotrienes (LTs; LTC4, LTD4, and LTE4), only LTE4 is stable and abundant in vivo. Although LTE4 shows negligible activity at the type 1 and 2 receptors for cys-LTs (CysLT1R and CysLT2R), it is a powerful inducer of mucosal eosinophilia and airway hyperresponsiveness in humans with asthma. We show that the adenosine diphosphate (ADP)–reactive purinergic (P2Y12) receptor is required for LTE4-mediated pulmonary inflammation. P2Y12 receptor expression permits LTE4 -induced activation of extracellular signal-regulated kinase in Chinese hamster ovary cells and permits chemokine and prostaglandin D2 production by LAD2 cells, a human mast cell line. P2Y12 receptor expression by LAD2 cells is required for competition between radiolabeled ADP and unlabeled LTE4 but not for direct binding of LTE4, suggesting that P2Y12 complexes with another receptor to recognize LTE4. Administration of LTE4 to the airways of sensitized mice potentiates eosinophilia, goblet cell metaplasia, and expression of interleukin-13 in response to low-dose aerosolized allergen. These responses persist in mice lacking both CysLT1R and CysLT2R but not in mice lacking P2Y12 receptors. The effects of LTE4 on P2Y12 in the airway were abrogated by platelet depletion. Thus, the P2Y12 receptor is required for proinflammatory actions of the stable abundant mediator LTE4 and is a novel potential therapeutic target for asthma.


Abbreviations used: 2-MesAMP, 2-methylthioadenosine monophosphate; 5-LO, 5-lipoxygenase; ADP, adenosine diphosphate; AERD, aspirin-exacerbated respiratory disease; BAL, bronchoalveolar lavage; cDNA, complementary DNA; CHO, Chinese hamster ovary; COX, cyclooxygenase; Cys-LT, cysteinyl LT; Der f, Dermatophagoides farinae; ERK, extracellular signal-regulated kinase; GPCR, G protein–coupled receptor; HIS, polyhistidine; LT, leukotriene; MC, mast cell; MIP-1β, macrophage inflammatory protein 1β; mRNA, messenger RNA; P2Y, purinergic; PAS, periodic acid–Schiff; PG, prostaglandin; PTX, pertussis toxin; shRNA, short hairpin RNA.

© 2009 Paruchuri et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS